

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
Give P values as exact values whenever suitable.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection Amber 16, Autodock vina 1.1.2, PHASER, COOT, PHENIX, MestReNova, DAWN-EOS detector, iTC200 microcalorimeter, , SYNAPT-G2-Si mass spectrometer, Thermo-Dionex Ultimate 3000 HPLC system,

Data analysis Amber 16, PyMol 2.1, PHASER, COOT 0.9.4, PHENIX, MestReNova, Origin 2019, Graphpad Prism 8.0, CCP4 suit, HKL2000 package, ASTRA software, MicroCal ITC200 analysis software Origin 7.0

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

The raw RNAseq data generated in this study have been deposited in the sequence read archive (SRA) repository of NCBI under BioProject accessions: PRJNA1138801 [<https://www.ncbi.nlm.nih.gov/bioproject/1138801>]. The crystal structure of PYL1-DBSA complex can be accessed from the Protein Data Band under

Research involving human participants, their data, or biological material

Policy information about studies with [human participants or human data](#). See also policy information about [sex, gender \(identity/presentation\), and sexual orientation](#) and [race, ethnicity and racism](#).

Reporting on sex and gender	<input type="text" value="There was no experiment involving human."/>
Reporting on race, ethnicity, or other socially relevant groupings	<input type="text" value="There was no experiment involving human."/>
Population characteristics	<input type="text" value="There was no experiment involving human."/>
Recruitment	<input type="text" value="There was no experiment involving human."/>
Ethics oversight	<input type="text" value="There was no experiment involving human."/>

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

- Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	<input type="text" value="Sample sizes were chosen based on what could be practically handled and good practice in the research field."/>
Data exclusions	<input type="text" value="No data was excluded."/>
Replication	<input type="text" value="All experiments were performed at least twice and numbers of replications have been provided in the figure legends."/>
Randomization	<input type="text" value="Randomization does not apply to the type of functional experiments in this study."/>
Blinding	<input type="text" value="Blinding does not apply to the type of functional experiments in this study."/>

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

- | | |
|-------------------------------------|--|
| n/a | Included in the study |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Antibodies |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Eukaryotic cell lines |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Palaeontology and archaeology |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Animals and other organisms |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Clinical data |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Dual use research of concern |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> Plants |

Methods

- | | |
|-------------------------------------|---|
| n/a | Included in the study |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> ChIP-seq |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Flow cytometry |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> MRI-based neuroimaging |

Dual use research of concern

Policy information about [dual use research of concern](#)

Hazards

Could the accidental, deliberate or reckless misuse of agents or technologies generated in the work, or the application of information presented in the manuscript, pose a threat to:

- | No | Yes | |
|-------------------------------------|--------------------------|----------------------------|
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | Public health |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | National security |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | Crops and/or livestock |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | Ecosystems |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | Any other significant area |

Experiments of concern

Does the work involve any of these experiments of concern:

- | No | Yes | |
|-------------------------------------|--------------------------|---|
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | Demonstrate how to render a vaccine ineffective |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | Confer resistance to therapeutically useful antibiotics or antiviral agents |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | Enhance the virulence of a pathogen or render a nonpathogen virulent |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | Increase transmissibility of a pathogen |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | Alter the host range of a pathogen |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | Enable evasion of diagnostic/detection modalities |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | Enable the weaponization of a biological agent or toxin |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | Any other potentially harmful combination of experiments and agents |

Plants

Seed stocks

PYL dimer and monomer multiple deletion mutant seeds (pyr1/pyl1/pyl2/pyl4) and PYL monomer multiple deletion mutant seeds (pyl3/pyl7/pyl9/pyl11/pyl12) were provided by Prof. Jian-Kang Zhu and Prof. Yang Zhao at Shanghai Center for Plant Stress Biology, Chinese Academy of Sciences, respectively, and pyl4 overexpression seeds were provided by Prof. Yuan Zheng at Henan University.

Novel plant genotypes

No

Authentication

PYL dimer and monomer multiple deletion mutant seeds (pyr1/pyl1/pyl2/pyl4) were provided by Prof. Jian-Kang Zhu at Shanghai Center for Plant Stress Biology, Chinese Academy of Sciences. PYL monomer multiple deletion mutant seeds (pyl3/pyl7/pyl9/pyl11/pyl12) were provided by Prof. Yang Zhao at Shanghai Center for Plant Stress Biology, Chinese Academy of Sciences and pyl4 overexpression seeds were provided by Prof. Yuan Zheng at Henan University.